{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:29:20Z","timestamp":1790342960948,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.phrs.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T15:15:36Z","timestamp":1530976536000},"page":"280-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives"],"prefix":"10.1016","volume":"134","author":[{"given":"Femke","family":"de Velde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2018.07.005_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.phrs.2018.07.005_bib0010","series-title":"Guideline on the Use of Pharmacokinetics and Pharmacodynamics in the Development of Antimicrobial Medicinal Products","author":"European Medicines Agency","year":"2016"},{"issue":"10","key":"10.1016\/j.phrs.2018.07.005_bib0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cmi.2015.06.007","article-title":"Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective","volume":"21","author":"Muller","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"10.1016\/j.phrs.2018.07.005_bib0020","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.07.005_bib0030","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2018.07.005_bib0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does Beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.phrs.2018.07.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkv201","article-title":"Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for?","author":"Huttner","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.phrs.2018.07.005_bib0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2018.07.005_bib0060","article-title":"MIC-based dose adjustment: facts and fables","author":"Mouton","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0065","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.phrs.2018.07.005_bib0070","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.phrs.2018.07.005_bib0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijantimicag.2009.08.005","article-title":"Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections","volume":"34","author":"Berthoin","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.phrs.2018.07.005_bib0080","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.47.9.2749-2755.2003","article-title":"Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration\/MIC versus area under the curve\/MIC ratios","volume":"47","author":"Scaglione","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bcp.12636","article-title":"Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients","volume":"80","author":"Schleibinger","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0090","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/clpt.1981.90","article-title":"Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics","volume":"29","author":"Stoeckel","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2018.07.005_bib0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn?","volume":"61","author":"Mouton","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.phrs.2018.07.005_bib0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","article-title":"Antimicrobial dosing considerations in obese adult patients","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0105","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.phrs.2018.07.005_bib0110","first-page":"e6","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharm. Syst. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.phrs.2018.07.005_bib0120","first-page":"e38","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharm. Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2018.07.005_bib0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.phrs.2018.07.005_bib0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","article-title":"Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian","volume":"40","author":"Tatarinova","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/096228029800700106","article-title":"Statistical methods for population pharmacokinetic modelling","volume":"7","author":"Racine-Poon","year":"1998","journal-title":"Stat. Methods Med Res."},{"issue":"4","key":"10.1016\/j.phrs.2018.07.005_bib0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10928-016-9476-y","article-title":"Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models","volume":"43","author":"Liu","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"4","key":"10.1016\/j.phrs.2018.07.005_bib0145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-199834010-00003","article-title":"Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new\u2019 multiple model\u2019 dosage design, bayesian feedback and individualised target goals","volume":"34","author":"Jelliffe","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.phrs.2018.07.005_bib0155","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1007\/s11095-006-9116-0","article-title":"Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets","volume":"23","author":"Proost","year":"2006","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0160","first-page":"639","article-title":"Population pharmacokinetic modelling, Monte carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy","volume":"72","author":"Llanos-Paez","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.phrs.2018.07.005_bib0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/dkq449","article-title":"Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients","volume":"66","author":"Roberts","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-200140010-00002","article-title":"A brief introduction to Monte Carlo simulation","volume":"40","author":"Bonate","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.phrs.2018.07.005_bib0175","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/jac\/dkw226","article-title":"Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints","volume":"71","author":"de Velde","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2018.07.005_bib0180","series-title":"Nonlinear Parametric and Nonparametric Population Pharmacokinetic Modeling on a Supercomputer, Technical Report 99-1","author":"Jelliffe","year":"1999"},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0185","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/jac\/dkw592","article-title":"Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis","volume":"72","author":"Konig","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0190","first-page":"791","article-title":"Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery","volume":"72","author":"De Cock","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2018.07.005_bib0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2018.07.005_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky071","article-title":"Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study","author":"Bos","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2018.07.005_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2017.02.021","article-title":"Impact of high-flux haemodialysis on the probability of target attainment for oral amoxicillin\/clavulanic acid combination therapy","author":"Hui","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.phrs.2018.07.005_bib0210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkx477","article-title":"Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection","volume":"73","author":"Goutelle","year":"2018","journal-title":"J Antimicrob Chemother."},{"issue":"10","key":"10.1016\/j.phrs.2018.07.005_bib0215","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1128\/AAC.01157-15","article-title":"Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice","volume":"59","author":"Smits","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","article-title":"Clinical pharmacodynamics of quinolones","volume":"17","author":"Ambrose","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0225","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/AAC.40.3.627","article-title":"Twenty-four-hour area under the concentration-time curve\/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model","volume":"40","author":"Madaras-Kelly","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0230","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2018.07.005_bib0235","series-title":"Prescribing Information Cipro IV (R) (Ciprofloxacin) Injection, for Intravenous Use","author":"Bayer","year":"2016"},{"key":"10.1016\/j.phrs.2018.07.005_bib0240","series-title":"Summary of Product Characteristics: Ciprofloxacin for Infusion","author":"Fresenius","year":"2017"},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0245","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","article-title":"Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study","volume":"23","author":"van Zanten","year":"2008","journal-title":"J. Crit. Care"},{"issue":"10","key":"10.1016\/j.phrs.2018.07.005_bib0250","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/AAC.49.10.4009-4014.2005","article-title":"Evaluating ciprofloxacin dosing for pseudomonas aeruginosa infection by using clinical outcome-based Monte carlo simulations","volume":"49","author":"Zelenitsky","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.phrs.2018.07.005_bib0255","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/jac\/dkr220","article-title":"Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations","volume":"66","author":"Khachman","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0260","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04337.x","article-title":"The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens","volume":"75","author":"Haeseker","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.005_bib0265","series-title":"Ciprofloxacin Bayer","author":"European Medicines Agency","year":"2008"},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring committee of the International association for therapeutic drug M, clinical T. Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.phrs.2018.07.005_bib0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003088-199834040-00001","article-title":"Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?","volume":"34","author":"Ensom","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.005_bib0290","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-14-288","article-title":"How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"7","key":"10.1016\/j.phrs.2018.07.005_bib0295","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2018.07.005_bib0300","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"10.1016\/j.phrs.2018.07.005_bib0305","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","article-title":"The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections","volume":"43","author":"Tangden","year":"2017","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.phrs.2018.07.005_bib0310","article-title":"Scalpels not hammers: the way forward for precision drug prescription","author":"Neely","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.005_bib0315","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2018.07.005_bib0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0325","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007691-199009000-00003","article-title":"Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis","volume":"12","author":"Destache","year":"1990","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.phrs.2018.07.005_bib0330","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Fernandez de Gatta","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2018.07.005_bib0335","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"Welty","year":"1994","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2018.07.005_bib0340","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/09031936.00149508","article-title":"Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia","volume":"34","author":"Scaglione","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.phrs.2018.07.005_bib0345","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.005_bib0350","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.ftd.0000243966.97964.11","article-title":"Pitfalls in TDM of antibiotic drugs: analytical and modelling issues","volume":"28","author":"Neef","year":"2006","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.phrs.2018.07.005_bib0355","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1211\/jpp\/61.06.0008","article-title":"Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients","volume":"61","author":"Mar Fernandez de Gatta","year":"2009","journal-title":"J. Pharm. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818307503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818307503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:59:27Z","timestamp":1760911167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818307503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":71,"alternative-id":["S1043661818307503"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.005","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}